BioCentury
ARTICLE | Clinical News

ShK-186: Phase Ib started

October 20, 2014 7:00 AM UTC

Kineta began a double-blind, placebo-controlled, Canadian Phase Ib trial to evaluate subcutaneous ShK-186 biweekly for 4 weeks in 24 patients. Kineta licensed the compound from Airmid in 2009 (see Bio...